nalm6 cells (DSMZ)
Structured Review
![( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM <t>(Jurkat,</t> <t>Nalm6,</t> K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_3651/pmc13693651/pmc13693651__sciadv.aea1431-f1.jpg)
Nalm6 Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 97/100, based on 498 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nalm6/NALM-6/pmc13693651-162-0-8
Average 97 stars, based on 498 article reviews
Images
1) Product Images from "NRF2 coordinates cystine import and glutathione use to sustain ferroptosis resistance and formaldehyde tolerance in cancer"
Article Title: NRF2 coordinates cystine import and glutathione use to sustain ferroptosis resistance and formaldehyde tolerance in cancer
Journal: Science Advances
doi: 10.1126/sciadv.aea1431
Figure Legend Snippet: ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM (Jurkat, Nalm6, K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .
Techniques Used: Concentration Assay, Comparison, Clonogenic Cell Survival Assay, Expressing, Control, Western Blot, Plasmid Preparation
Related Articles
Cell Culture:Article Title: Exploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting. Article Snippet: Cells were transduced on two consecutive days with cryopreserved MSCV-IRES-GFP (empty vector), MSCV-IRES GFP BCRABL1- (as in vitro model for murine B-ALL) or MSCV-IRES GFP MLLAF9- (as in vitro model for murine AML) expressing retroviri. .. The human leukemic cell lines K562 (BCR-ABL1+; myeloid, model of CML) (ACC10), Article Title: High-throughput ligand diversification to discover chemical inducers of proximity. Article Snippet: OCI-AML2 (gift from J. Bradner), OCI-AML3 (German Collection of Microorganisms and Cell Cultures (DSMZ), ACC 582) and Kasumi-1 (American Type Culture Collection (ATCC), CRL-2724) were cultured in 20% FBS in RPMI 1640. .. HB11;19 (gift from the laboratory of A. Yokoyama), Jurkat (gift of the laboratory of M. Bollong) MV4;11 and MOLM-13 (gifts from J. Bradner), Article Title: Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR Article Snippet: HEK-293T (ATCC;ATCCCRL-11268)were cultured in Iscove’smodifiedDulbecco’smedium(12-726F, Lonza) supplementedwith 10%FBS (Labtech) and 2 mM GlutaMAX (35050061, Invitrogen). .. SupT1 (ECACC; 95013123), other:Article Title: iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies anti-human CD2 BioLegend 300230; RRID:AB_2800713 anti-human CD3 Biolegend 317330; RRID:AB_11219196 anti-human CD4 BioLegend 344631; RRID:AB_2566014 anti-human CD5 BD Bioscience 555352; RRID:AB_395756 anti-human CD7 BD Bioscience 555361; RRID:AB_395764 anti-human CD8a BD Bioscience 612754; RRID:AB_2870085 anti-human CD8b eBioscience 25-5273-42; RRID:AB_11219680 anti-human CD10 BD Bioscience 564960; RRID:AB_2739025 anti-human CD107a BD Bioscience 555800; RRID:AB_396134 anti-human CD107b BD Bioscience 555804; RRID:AB_396138 anti-human CD16 BD Bioscience 556619; RRID:AB_396491 anti-human CD25 BioLegend 356140; RRID:AB_2750205 anti-human CD27 BioLegend 356404; RRID:AB_2561788 anti-human CD28 BioLegend 302908; RRID:AB_314310 anti-human CD30 BD Bioscience 550041; RRID:AB_393541 anti-human CD38 BioLegend 397104; RRID:AB_2810611 anti-human CD45 BD Bioscience 563792; RRID:AB_2869519 anti-human CD45RA BD Bioscience 555488; RRID:AB_395879 anti-human CD62L BD Bioscience 559772; RRID:AB_398668 anti-human LAG3 BioLegend 369310; RRID:AB_2629753 anti-human PD1 eBioscience 12-2799-42; RRID:AB_11042478 anti-human MICA/B (clone 7C6) Andrade et al. 30 N/A anti-human SSEA4 BD Bioscience 560126; RRID:AB_1645491 anti-human TCRv13.1 Beckman Coulter IM2292 anti-human TIM3 BioLegend 345016; RRID:AB_2561934 anti-human TRA181 BD Bioscience 560793; RRID:AB_10550550 anti-ID BCMA CAR This paper N/A anti-human pCD3z BD Bioscience 558486; RRID:AB_647104 anti-human pERK BD biosciences 612593; RRID:AB_399876 anti-human pLAT BD biosciences 558518; RRID:AB_647131 anti-human pSLP76 BD biosciences 558439; RRID:AB_647107 anti-human pZAP70 BD biosciences 557818; RRID:AB_396885 anti-human Interferon-γ Biolegend 502532; RRID:AB_2561398 anti-human TNFα Biolegend 502948; RRID:AB_2565858 human Fc Block BD Bioscience 564220; RRID:AB_2869554 mouse Fc Block BD Bioscience 553142; RRID:AB_394657 anti-mouse CD90.1 BioLegend 202529; RRID:AB_10899572 Biotinylated anti-human CD16 antibody Biolegend 302004; RRID:AB_314203 anti-CD19 (MDX-1342) antibody Creative Biolabs AFC-104CL anti-PD-L1 (Avelumab) antibody MedChemExpress HY-108730 anti-EGFR (Cetuximab) antibody MedChemExpress HY-P9905 Anti-HER2 (Herceptin) antibody Roche PZN-01289787 anti-CD38 (Daratumumab) antibody DARZALEX DARZALEX (Continued on next page) e1 Cell Reports Medicine 6, 102195, July 15, 2025 OPEN ACCESS Article Title: iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors Article Snippet: Female 6-8 weeks old NSG mice (NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ) were purchased from The Jackson Laboratory (RRID:IMSR, Cat. 005557). |


